Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell, it was time …

May 15, 2017 6:17pm

For the oversold to be recognized

… The question remains, how do we measure truly performance?

A provisional high against a durable low?

Pre-open indications: 0 hits and 6 miss

As the leading voice of cell therapy investors; I am not always a doom and gloom reporter but a man who has been “there” with the gray hair and a readership following with real numbers to prove it!

I answer one question, in which company should investors commit and keep their money

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

Henry’omics:

From the pre-open’s investor’s newsletter “What will restore faith in the sector?”

Reiterating, “As ROI is non-existent while the only sustainability is excessive pay packages which increase exponentially versus share pricing movement!”

Technically speaking, volatility, as measured by the CBOE Volatility Index VIX, +0.58% just touched on levels that haven’t been seen since 1993.

There is a BIG difference between “our” universe and the broader market …

Investors have gone with the flow of the positive versus negative close and the alternating advance/decline lines and there’s a sense the same old will continue!

Daily analytics:

U.S. equities closed UP on Monday … with the DOW closing UP +0.41% (+85.33) as the NASDAQ also closed up +0.46% (+28.44) …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded 10.4 ….

· Friday traded below 10 following Thursday’s near 10.6 following Wednesday‘s near 10,Tuesday traded below 10, not seen since December 2006 while Monday traded near 10;

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a positive +0.15% at the pre-open and closed UP +0.78%

… The iShares NASDAQ Biotechnology (IBB) indicated a +0.04% in the pre-open and closed UP +0.43%

The advance/decline line scenario of 43 SCGT & RT covered companies:

· The open was not captured;

· The mid-day positive with an A/DL of 26/16 and 1 flat;

· The close stayed positive with an A/DL of 27/12 and 4 flats;

The count - decliners versus gainers: look at the differences in the spreads and advance/decline lines:

· Monday’s decliners ranged from -0.04% <KITE> to -4.41% <MESO> in 12 equities;

· Friday’s decliners ranged from -0.13% <MDXG> to -61.97% <CAPR> in 12 equities;

· Thursday’s decliners ranged from -0.20% <CLBS> to -5.04% <AGTC> in 21 equities;

· Wednesday’s decliners ranged from -0.48% <VTGN> to -7.92% <RGNX> in 14 equities;

· Tuesday’s decliners ranged from -0.07% <MDXG> to -27.70% <CUR> in 22 equities;

· Last Monday’s decliners ranged from -0.65% <CAPR> to -13.56% <CUR> in 28 equities;

Versus

· Monday’s gainers ranged from +0.19% <BSTG> to +9.50% <FCSC> in 27 equities;

· Friday’s gainers ranged from +0.40% <BLUE> to +17.14% <SGMO> in 30 equities;

· Thursday’s gainers ranged from +0.09% <KITE> to +60.92% <SGMO> in 19 equities;

· Wednesday’s gainers ranged from +0.03% <OPXA> to +36.18% <CUR> in 27 equities;

· Tuesday’s gainers ranged from +0.04% <CLLS> to +6.41% <JUNO> in 18 equities;

· Last Monday’s gainers ranged from +0.37% <ONVO> to +11.84% <OSIR> in 12 equities;

Pre-open indications: 2 hit and 4 miss

AxoGen (AXGN) closed up +$0.45 – miss;
Capricor (CAPR) closed up +$0.03 – miss;
Kite Pharma (KITE) closed down -$0.03 – miss;
Intrexon (XON) closed up +$1.53 – miss;
Osiris (OSIR) closed up +$0.11 – miss;
Sangamo (SGMO) closed up +$0.20 – miss;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 2 min ago
RegMed Investors’ (RMi) pre-open: what goes down, goes up as earnings sees their shadow

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.